Two Molecules, One Cellular-Energy Question

The short version

Living Water Peptides is a reading desk, not a store. It collects what the published research literature actually says about two molecules that keep appearing in conversations about longevity and cellular health: NAD+ and MOTS-c. A peptide is a short chain of amino acids — the same building blocks as proteins, only smaller. MOTS-c is a true peptide, just 16 amino acids long. NAD+ is not a peptide at all; it is a coenzyme, a small molecule the cell uses to transfer electrons during energy production. They appear here together because they share a theme: both are understood through the lens of mitochondrial biology and metabolic aging.

This desk does one job: it tells you, in plain language and with citations, what each molecule was tested on, in which species, and how far that evidence really reaches. For NAD+ precursors, human evidence exists and is growing — though its translation to long-term clinical outcomes remains an open question. For MOTS-c, the evidence is largely from animals. Neither is an approved medicine for longevity. This site does not sell anything, gives no medical advice, and lists no human dose.

What are research peptides?

Proteins in your body — a structural fiber in your muscle, a hormone, an enzyme — are long chains of amino acids folded into a working shape. A peptide is a much shorter chain of the same amino acids, sometimes only a few links long. Because they are small and specific, peptides can act like keys that fit particular receptor-locks on cell surfaces, switching certain processes on or off.

A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, animals, occasionally early human pilots — but has not been approved by a regulator as a medicine. Sellers describe these compounds as being for laboratory research only, and that framing matters: it means dosing, long-term safety, and real-world effectiveness in people are usually unestablished. When this site reports a number, it reports it exactly as the study did — for example, studied at 5 mg/kg in mice — never as a recommendation. Where a molecule derives from a natural endogenous source, this desk says so, because that lineage is often the key to understanding its mechanism.

How these two fit into longevity and cellular-energetics research

NAD+ and MOTS-c approach cellular aging from complementary angles, which is why they sit together on this desk.

• NAD+ is the lead. It is not a peptide but the cell's central redox coenzyme — a molecule that carries electrons through glycolysis, the TCA cycle, and oxidative phosphorylation to produce ATP — and also a substrate consumed by signaling enzymes (sirtuins, PARPs, CD38) that govern DNA repair and inflammation ^[4]. NAD+ levels fall with age, partly because the enzyme CD38 rises with age and consumes it ^[6]. Human trials with precursors such as NMN and NR have consistently raised blood NAD+, though a 2025 review concluded translation to hard clinical endpoints remains inconsistent and tissue-specific data sparse ^[1].
• MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome's 12S rRNA gene — the first mitochondrially encoded peptide shown to translocate to the nucleus and regulate nuclear gene expression ^[12]. Its primary mechanism runs through AMPK activation, and exogenous MOTS-c improved physical performance across young, middle-aged, and old mice in a 2021 Nature Communications study ^[11]. Human data are observational biomarker associations, not interventional outcomes.

Together they sketch cellular aging from two sides: the metabolic-currency angle (NAD+) and the mitochondrial-signaling angle (MOTS-c). Use the directory to read each one, or compare these two side by side.

A note on how this desk reads the literature

Living Water Peptides is a cross-referenced literature digest. Each page summarizes the peer-reviewed studies for that molecule, cites them by number, and links to a single shared references list aggregating every source. Where the evidence is thin, single-lab, or preclinical only, this desk says so plainly — that caution is part of the record, not a footnote to it. Effect sizes, study designs, and sample sizes are reported because they are what distinguish a robust signal from a preliminary one. The aim is an accurate, data-forward map of what is known, so you can see where the science is solid and where it is still early promise.